NEWSFLOW

views

Shares in company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) are currently further higher today to 123p on the back of a “US EPA Authorises Grafysorber for Use in US”-titled announcement. What does this latest here mean?...

views

Having commenced November at a 136p share price, two subsequent announcements have helped shares in Directa Plus (DCTA) up to a current 160p. So what’s this latest news from this ‘graphene nanoplatelets-based products’ company?...

views

Previously writing on graphene nanoplatelets-based products company Directa Plus (DCTA), in June I concluded with the shares at 121.5p, having expressed cash burn concern, I continued to avoid. Today an “Additional Italian Government Covid Recovery Loan” announcement.

views

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) “is pleased to report that this strong revenue growth is continuing in the last two months of the current first half”. What does it mean financially?...

views

Having exceeded 140p in February, shares in self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) last closed at 112.5p and are currently further lower on the back of 2020 results announcement. So what’s the detail?...

views

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has been granted an EU-wide patent covering the use of its G+® graphene in golf ball applications”. It emphasises this “the first step towards addressing a very large global market” and the shares have responded currently 4% higher to 106p, a £65 million market capitalisation. Is this justified?...

views

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) has made a trading update including noting 2020 revenue “further improvement” from previously reported expectations, Q1 2021 revenue expected to be up 20% from the same period last year and that “there is a strong pipeline of opportunities”. Why are the shares though still well down from 145p reached earlier this year?...

views

A “Successful Absorption Evaluation Test”-titled announcement from Directa Plus (DCTA) re. its pristine graphene nanoplatelets powder through human skin, with it stated “our suite of successful in vitro tests proves to customers in the textile industry that they can safely adopt our products to create exciting new garments enhanced by our graphene products”. Exciting news?...

views

Directa Plus (DCTA) “is pleased to announce that the company has signed a supply agreement and a Strategic R&D Agreement with NexTech Batteries Inc., a leading company in the field of Lithium Sulphur batteries based in Nevada, US” – and the shares are currently more than 10% higher in response at 144p. So what’s the detail?...